Elsevier introduces new open-access journal on parasitology

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, in association with the Australian Society for Parasitology, is pleased to announce the launch of a new journal, International Journal for Parasitology: Drugs and Drug Resistance. The new electronic open access journal is closely affiliated with the leading parasitology journal, International Journal for Parasitology, and will address a critical area of research, covering anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal's remit also includes research into natural products as anti-parasitic agents, and bioactive parasite products.

Prof Terry Spithill, President of the Australian Society for Parasitology, said, "The Society is delighted to have fostered the founding of this new Journal which we anticipate will provide a stellar forum for the dissemination of original discoveries in the pharmacological control of parasites of human and veterinary significance."

Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. The Journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions". Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.

"We are delighted to continue our excellent relationship with the Australian Society for Parasitology, and are confident that IJP:DDR will quickly establish itself as the leading journal in its field," added Dale Seaton, Executive Publisher for Elsevier. "In addition, by utilizing the open access model option for this title, Elsevieris enabling the broadest possible access to quality research content in a sustainable way that meets the society's needs."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose